PAPER Li Y, Jiang J, Lu J, Jiang J, Zhang H, Zuo C

Radiomics: a novel feature extraction method for brain neuron degeneration disease using 18F-FDG PET imaging and its implementation for Alzheimer's disease and mild cognitive impairment.

Ther Adv Neurol Disord. 2019;12:1756286419838682. Epub 2019 Mar 29 PubMed.

PAPER Milà-Alomà M, Suárez-Calvet M, Molinuevo JL

Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease.

Ther Adv Neurol Disord. 2019;12:1756286419888819. Epub 2019 Dec 18 PubMed.

PAPER Pelizzari L, Laganà MM, Rossetto F, Bergsland N, Galli M, Baselli G, Clerici M, Nemni R, Baglio F

Cerebral blood flow and cerebrovascular reactivity correlate with severity of motor symptoms in Parkinson's disease.

Ther Adv Neurol Disord. 2019;12:1756286419838354. Epub 2019 Mar 21 PubMed.

PAPER Chung CC, Chan L, Chen JH, Bamodu OA, Hong CT

Neurofilament light chain level in plasma extracellular vesicles and Parkinson's disease.

Ther Adv Neurol Disord. 2020;13:1756286420975917. Epub 2020 Dec 7 PubMed.

PAPER Leocadi M, Canu E, Calderaro D, Corbetta D, Filippi M, Agosta F

An update on magnetic resonance imaging markers in AD.

Ther Adv Neurol Disord. 2020;13:1756286420947986. Epub 2020 Sep 4 PubMed.

PAPER Riesenberg R, Werth J, Zhang Y, Duvvuri S, Gray D

PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial.

Ther Adv Neurol Disord. 2020;13:1756286420911296. Epub 2020 Mar 6 PubMed.

PAPER Stuve O, Weideman RA, McMahan DM, Jacob DA, Little BB

Diclofenac reduces the risk of Alzheimer's disease: a pilot analysis of NSAIDs in two US veteran populations.

Ther Adv Neurol Disord. 2020;13:1756286420935676. Epub 2020 Jun 25 PubMed.

PAPER Armstrong MJ

Advances in dementia with Lewy bodies.

Ther Adv Neurol Disord. 2021;14:17562864211057666. Epub 2021 Nov 23 PubMed.

PAPER Mora JS, Bradley WG, Chaverri D, Hernández-Barral M, Mascias J, Gamez J, Gargiulo-Monachelli GM, Moussy A, Mansfield CD, Hermine O, Ludolph AC

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis.

Ther Adv Neurol Disord. 2021;14:17562864211030365. Epub 2021 Jul 19 PubMed.

PAPER Shu ZY, Mao DW, Xu YY, Shao Y, Pang PP, Gong XY

Prediction of the progression from mild cognitive impairment to Alzheimer's disease using a radiomics-integrated model.

Ther Adv Neurol Disord. 2021;14:17562864211029551. Epub 2021 Jul 15 PubMed.

PAPER Achenbach J, Saft C, Faissner S, Ellrichmann G

Positive effect of immunomodulatory therapies on disease progression in Huntington's disease? Data from a real-world cohort.

Ther Adv Neurol Disord. 2022;15:17562864221109750. Epub 2022 Jul 23 PubMed.

PAPER Kim Y, Seo SI, Lee KJ, Kim J, Yoo JJ, Seo WW, Lee HS, Shin WG

Long-term use of proton-pump inhibitor on Alzheimer's disease: a real-world distributed network analysis of six observational Korean databases using a Common Data Model.

Ther Adv Neurol Disord. 2022;15:17562864221135700. Epub 2022 Nov 8 PubMed.

PAPER Zhu JD, Huang CW, Chang HI, Tsai SJ, Huang SH, Hsu SW, Lee CC, Chen HJ, Chang CC, Yang AC

Functional MRI and ApoE4 genotype for predicting cognitive decline in amyloid-positive individuals.

Ther Adv Neurol Disord. 2022;15:17562864221138154. Epub 2022 Nov 19 PubMed.

PAPER Chan L, Chung CC, Hsieh YC, Wu RM, Hong CT

Plasma extracellular vesicle tau, β-amyloid, and α-synuclein and the progression of Parkinson's disease: a follow-up study.

Ther Adv Neurol Disord. 2023;16:17562864221150329. Epub 2023 Feb 1 PubMed.

PAPER Stopschinski BE, Weideman RA, McMahan D, Jacob DA, Little BB, Chiang HS, Saez Calveras N, Stuve O

Microglia as a cellular target of diclofenac therapy in Alzheimer's disease.

Ther Adv Neurol Disord. 2023;16:17562864231156674. Epub 2023 Feb 27 PubMed.